Skip to content

3D Transcranial Ultrasound Brain Imaging (3D-TRUBI) Instrument for Point-of-Care Diagnosis of Intracranial Hemorrhages

3D Transcranial Ultrasound Brain Imaging (3D-TRUBI) Instrument for Point-of-Care Diagnosis of Intracranial Hemorrhages Caused by Traumatic Brain Injuries

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06780436
Acronym
3D-TRUBI
Enrollment
20
Registered
2025-01-17
Start date
2024-12-04
Completion date
2026-09-30
Last updated
2025-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

3D SONOGRAPHY, Intracranial Hemorrhages, Traumatic Brain Hemorrhage, Traumatic Brain Injury, Ultrasound Exams

Keywords

transcranial ultrasound, traumatic brain injury, intracranial hemorrhage, ultrasound

Brief summary

The primary objective of this study is to assess the safety of the 3D Transcranial Ultrasound Brain Imaging (3D TRUBI) device in Traumatic Brain Injury (TBI) patients with intracranial hemorrhage (ICH). The secondary objective is to assess the diagnostic potential of 3D TRUBI. The latter will be achieved by comparison of 3D TRUBI scans with admission head computed tomography (CT), the standard of care diagnostic modality. Demonstrating the feasibility and safety of the 3D TRUBI system is the first step toward expanding access of an alternative to CT for diagnostic imaging and triage of mass casualties of war or natural disasters in the field and in rapidly deployed medical centers or other austere environments.

Detailed description

Eligible participants positive for intracranial hemorrhage (ICH) due to traumatic brain injury (TBI) will undergo a full scanning procedure by trained investigators. Examination with the 3D TRUBI system will involve acquisition of 16 pre-defined bilateral head points. The total time to complete the procedure is approximately 20 minutes. During the examination, feasibility and safety metrics will be collected. Additional injury data will be reviewed from participants' electronic medical record. The goal of the study is 1) to evaluate the safety of the 3D TRUBI device in the target population and 2) do demonstrate the feasibility of the device to detect ICH compared to standard medical imaging.

Interventions

DEVICE3D Transcranial Ultrasound Brain Imaging

The system implements a proprietary transcranial imaging methodology, which measures the profile of the skull bone and the speed of sound in it to accurately focus the ultrasound energy from a phased array probe through the bone in order to detect hematoma boundaries with resolution normally obtainable only through the open skull.

Sponsors

Brooke Army Medical Center
CollaboratorFED
Uniformed Services University of the Health Sciences
CollaboratorFED
The Geneva Foundation
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-89 * Acute head injury with CT-confirmed intracranial hemorrhage * Able to obtain written, informed consent from participant or legally authorized representative * Able to receive intervention within 4 hours of admission head CT * Able to feasibly receive intervention prior to neurosurgical indication

Exclusion criteria

* Did not receive routine head CT * Prisoner or Wards of State * Large or open skull wounds prohibiting ultrasound acquisition * Received large volume fluid resuscitation (e.g. \>3 units of blood product) within 2 hours of intervention * Any prohibiting condition or contraindication for ultrasound image acquisition

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of Intracranial Hemorrhage DetectionFrom enrollment to the end of data analysis (18 months)The primary outcome is the assessment of the feasibility of 3D-TRUBI for the detection of ICH and other traumatic brain lesions as compared to admission head CT. This is a binary parameter for each type of lesion per patient.
Evaluation of potential adverse effectsup to 48 hours after enrollmentParticipants will be evaluated for any potential adverse reactions to performance of the TRUBI exam during and after the research procedure. Twenty-four and 48-hour examination of the head are also planned to record potential adverse reactions.

Secondary

MeasureTime frameDescription
Morphometric comparison of 3D-TRUBI with Standard RadiologyFrom enrollment to end of data analysis (18 months)If the ICH lesion is detectable on CT, the conventional morphometric analysis of the lesion (maximum thickness, width, and length) and midline shift will be compared with morphometric analysis of the same lesions on 3D-TRUBI images. Measurements of ICH lesions by both modalities will be done in mm (millimeters), so there will be direct numerical comparisons of results using descriptive statistics, and other types of correlation and regression analyses.
Feasibility of 3D-TRUBI Assessment for Detection of Intracranial HemorrhageFrom enrollment to discharge of subject (7 days)To address feasibility of deployment of the 3D-TRUBI for ICH detection in the acute care setting, we will collect and analyze the time required to recruit, enroll, initiate, complete, and (where appropriate) repeat the assessment for ICH detection.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026